Active ingredient containing miRNA and application thereof

Through miRNA or derivatives of the miR-302/miR367 family, the lack of drugs in the prior art to reverse cell aging is solved, and the regeneration and proliferation of senescent cells and the therapeutic effect of aging diseases is achieved.

CN119055671APending Publication Date: 2024-12-03YUANSHENG BIOTECH (TSING DAO) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411018780.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-23
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art lacks effective miRNA drugs related to reverse aging, making it difficult to solve the problem of cellular aging.

Method used

An active ingredient, including miRNAs of the miR-302/miR367 family or modified derivatives thereof, is provided to process miRNAs in the host by expression vectors or polynucleotides, for reverse cellular senescence and reenter senescent cells into the cell cycle.

Benefits of technology

Through in vitro cell assays and in vivo animal experiments, miRNAs from the miR-302/367 family can reverse aging cells and return them to the cell cycle, significantly delaying or reversing the aging process, and are used to treat aging and related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004966811960000051
    Figure BDA0004966811960000051
  • Figure BDA0004966811960000071
    Figure BDA0004966811960000071
  • Figure BDA0004966811960000101
    Figure BDA0004966811960000101
Patent Text Reader

Abstract

The invention relates to an active component containing miRNA and application of the active component. The active component comprises miRNA of a miR-302 / miR367 family or a modified miRNA derivative of the miR-302 / miR367 family. The active ingredient can prevent or treat overactive bladder.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application with application number 202310592232.X, application date May 23, 2023, and invention name “Active ingredients containing miRNA and their applications”. Technical Field

[0002] The present application belongs to the field of biomedicine, and specifically relates to active ingredients containing miRNA and their applications. Background Art

[0003] Aging is a process that all life has to face. How to find ways to crack the biological mechanism of aging and find methods and drugs to delay or reverse aging has always been a hot topic in the scientific community. At the same time, it also has great social significance and huge commercial value. Aging is divided into several levels: individual aging, organ aging, and cell aging. The aging of individuals and organs is ultimately reflected in cell aging. From the perspective of drug research and development, it is a reasonable solution to obtain drugs that delay or reverse cell aging and then apply them to animals.

[0004] MicroRNA (miRNA) is a non-coding single-stranded RNA molecule with a length of 18-25 nucleotides encoded by endogenous genes. MiRNA is involved in a variety of biological processes. One way is that miRNA binds to the target gene complementary to the target gene and finally cuts the target mRNA. The second way is that it binds to the target gene in an incompletely complementary way and inhibits the translation of the target gene.

[0005] The seed sequence of miRNA is the most evolutionarily conserved sequence, generally the 2nd to 8th nucleotides at the 5' end. The conservation of the seed sequence and the target sequence constitutes the model basis for target sequence prediction, but the predicted target sequences still need to be experimentally verified.

[0006] Currently, there is a lack of effective therapeutic miRNA drugs that reverse aging. Summary of the invention

[0007] Based on this, it is necessary for the present application to provide an active ingredient that is found to be able to reverse the aging process, for example, restore senescent cells to re-enter the cell cycle or restore the proliferation ability of senescent cells. Further, it is used in the treatment of aging or aging-related diseases.

[0008] The specific technical solutions are as follows:

[0009] The present application provides an active ingredient, which includes at least one of the following:

[0010] (1) miRNAs of the miR-302 / miR367 family, or modified miRNA derivatives of the miR-302 / miR367 family, or miRNA mimics of the miR-302 / miR367 family;

[0011] (2) a precursor miRNA, which can be processed into the miRNA described in (1) in the host;

[0012] (3) a polynucleotide, which can be transcribed by a host to form the precursor miRNA described in (2), and processed to form the miRNA described in (1);

[0013] (4) an expression vector comprising the miRNA described in (1), the precursor miRNA described in (2), or the polynucleotide described in (3);

[0014] (5) An agonist of the miRNA described in (1).

[0015] In one embodiment, the miRNA is derived from humans or other animals. Optionally, the other animals include one or more of primates and other mammals, amphibians and birds. Optionally, the other animals include one or more of monkeys, mice and rats.

[0016] In one embodiment, the miRNA of the miR-302 / 367 family includes one or more of miR-302a, miR-302b, miR-302c, miR-302d, miR-302e, miR-302f and miR-367. Optionally, the miR-302a includes miR-302a-3p and / or miR-302a-5p; the miR-302b includes miR-302b-3p and / or miR-302b-5p; the miR-302c includes miR-302c-3p and / or miR-302c-5p; the miR-302d includes miR-302d-3p and / or miR-302d-5p; the miR-367 includes miR-367-3p and / or miR-367-5p.

[0017] In one embodiment, the miRNA of the miR-302 / 367 family is selected from one or more of the following: hsa-miR-302a-3p, hsa-miR-302b-3p, hsa-miR-302c-3p.1, hsa-miR-302d-3p, hsa-miR-302e, bta-miR-302b, bta-miR-302c, bta-miR-302d, gga-miR-302b-3p, gga-miR-302c-3p, gga-miR-302d, mdo- miR-302a, mdo-miR-302b, mdo-miR-302c, mdo-miR-302d, mml-miR-302a-3p, mml-miR-302b, mml-miR-302c, mml-miR-302d, mm u-miR-302a-3p, mmu-miR-302b-3p, mmu-miR-302d-3p, ptr-miR-302a, ptr-miR-302b, ptr-miR-302c, ptr-miR-302d, ptr-miR- 302e, hsa-miR-302a-5p, cfa-miR-302a, mmu-miR-302a-5p, hsa-miR-302b-5p, hsa-miR-302d-5p, cfa-miR-302b, cfa-miR-30 2d, gga-miR-302b-5p, mmu-miR-302b-5p, mmu-miR-302c-5p, mmu-miR-302d-5p, bta-miR-302a, gga-miR-302a, mmu-miR-302c -3p, hsa-miR-302c-5p, cfa-miR-302c, gga-miR-302c-5p, hsa-miR-302f, ptr-miR-302f, hsa-miR-367-5p, cfa-miR-367, mmu -miR-367-5p, hsa-miR-367-3p, mml-miR-367, mmu-miR-367-3p, ptr-miR-367, gga-miR-367, mml-miR-302a-5p and xtr-miR-367.

[0018] In one embodiment, the nucleotide sequence of the miRNA of the miR-302 / 367 family comprises a nucleotide sequence as shown in at least one of SEQ ID Nos: 1 to 14.

[0019] The present application also provides the use of the above-mentioned active ingredients in the preparation of products for reversing the aging process of senescent cells.

[0020] The present application also provides the use of the above-mentioned active ingredients in the preparation of products for restoring the cell cycle or cell proliferation ability of senescent cells.

[0021] The present application also provides the use of the above-mentioned active ingredients in the preparation of products for treating diseases related to cell aging.

[0022] Compared with the prior art, this application has the following beneficial effects:

[0023] Through in vitro cell experiments and in vivo animal experiments, the present application discovered that miRNAs in the miR-302 / 367 family or miRNAs with substantially the same functions and the same core sequences can reverse senescent cells and allow senescent cells to return to the cell cycle and proliferate, the so-called "rejuvenation". They can be used as active ingredients for reversing aging and for treating aging and aging-related diseases, such as overactive bladder. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1A This is the result of flow cytometry sorting; Figure 1B Detection of senescence of p21-YFP-Neo cell line Expression of p21-YFP under fluorescence microscopy; Figure 1C is the β-gal staining picture;

[0025] Figure 2 The proliferation of senescent cells after treatment with mir-302b;

[0026] Figure 3 To track the proliferation of senescent cells treated with miR-302b with high content, each image was taken 6 hours apart;

[0027] Figure 4 The proliferation of senescent cells after treatment with human miR-302a, miR-302b, miR-302c, miR-302d, miR-302e, miR-302f, and miR-367;

[0028] Figure 5 The results of flow cytometry cell cycle detection; Figure A is the flow cytometry graph, and Figure B is the quantification graph of Figure A;

[0029] Figure 6 This is the Ki67 staining result;

[0030] Figure 7 Construction process for pAAV-CMV-miR-302b;

[0031] Figure 8 Schematic diagram of packaging of recombinant AAV virus overexpressing miR-302b;

[0032] Fig. 9 This is a diagram showing the aging-alleviating changes after administration of mir-302b to old mice;

[0033] Fig.10 This is the result of organ β-gal staining;

[0034] Fig.11 This is the result of H&E staining of hair follicles;

[0035] Fig.12 For the rotarod test and grip strength results;

[0036] Fig.13 Results of urine spot test. DETAILED DESCRIPTION

[0037] In order to make the above-mentioned purposes, features and advantages of the present application more obvious and easy to understand, the specific implementation methods of the present application are described in detail below in conjunction with the accompanying drawings. In the following description, many specific details are set forth to facilitate a full understanding of the present application. However, the present application can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without violating the connotation of the present application, so the present application is not limited by the specific embodiments disclosed below.

[0038] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.

[0039] As used herein, the term "and / or" includes any and all combinations of one or more of the associated listed items.

[0040] Currently, senescent cells are defined as cells that have permanently terminated their cell cycle. However, this application found that senescent cells do not have permanently terminated their cell cycle, but rather temporarily stopped. Exogenous miRNA can be used to restore senescent cells and allow them to re-enter the cell cycle. This discovery is a disruptive result that will bring new ideas and new potential drugs to the major problem of aging that needs to be solved urgently.

[0041] Based on this, an embodiment of the present application provides an active ingredient, which includes at least one of the following groups:

[0042] (1) A miRNA or a modified miRNA derivative or miRNA mimic comprising at least one of the following core sequences, with a length of 16 nt to 28 nt, and having the same or substantially the same function as miR-302 or miR-367:

[0043] 5′-AAGUGCU-3′, 5′-CUUAAAC-3′, 5′-CUUUAAC-3′, 5′-AGUGCUU-3′, 5′-UUAACAU-3′, 5′-AAUUGCU-3′, 5′-CUGUUGC-3′, and 5′-AUUGCAC-3′;

[0044] (2) a precursor miRNA, which can be processed into the miRNA described in (1) in the host;

[0045] (3) a polynucleotide, which can be transcribed by a host to form the precursor miRNA described in (2), and processed to form the miRNA described in (1);

[0046] (4) an expression vector comprising the miRNA described in (1), the precursor miRNA described in (2), or the polynucleotide described in (3);

[0047] (5) An agonist of the miRNA described in (1).

[0048] In a specific example, the miRNA described in (1) can be a mature miRNA.

[0049] The term "miRNA and its precursor" refers to microRNA (miRNA for short), which is an endogenous non-coding single-stranded small RNA of about 22 nucleotides in length that has been found in eukaryotic organisms such as nematodes, fruit flies, plants, and mammals in recent years. It has tissue and time specificity in expression, and negatively regulates gene expression at the post-transcriptional level by complementary base pairing with the target mRNA, resulting in mRNA degradation or translation inhibition, and is an important regulatory molecule for regulating the expression of other functional genes. More and more evidence shows that although miRNA is small, it plays a vital role in various life processes of organisms by forming complete or incomplete mismatches with the target mRNA. As used herein, the "miRNA" refers to a class of RNA molecules that are processed from transcripts that can form miRNA precursors. Mature miRNAs usually have 18-26 nucleotides (nt) (more particularly about 19-22nt), and miRNA molecules with other numbers of nucleotides are not excluded. MiRNAs can usually be detected by Northern blots.

[0050] miRNA can be processed from precursor miRNA (Precursor miRNA, Pre-miRNA), and the precursor miRNA can be folded into a stable stem-loop (hairpin) structure, and the length of the stem-loop structure is generally between 50-100bp or longer. The precursor miRNA can be folded into a stable stem-loop structure, and the stem of the stem-loop structure contains two substantially complementary sequences on both sides. The precursor miRNA can be natural or artificially synthesized. As used herein, "substantially complementary" means that the nucleotide sequences are sufficiently complementary and can interact in a predictable manner, such as forming a secondary structure (such as a stem-loop structure). Usually, at least 70% of the nucleotides of two "substantially complementary" nucleotide sequences are complementary to each other; preferably, at least 80% of the nucleotides are complementary; more preferably, at least 90% of the nucleotides are complementary; further preferably, at least 95% of the nucleotides are complementary; such as 98%, 99% or 100%.

[0051] As used herein, a "stem-loop" structure is also referred to as a "hairpin" structure, and refers to a nucleotide molecule that can form a secondary structure including a double-stranded region (stem), wherein the double-stranded region is formed by two regions of the nucleotide molecule (located on the same molecule), and the two regions are arranged on both sides of the double-stranded portion; it also includes at least one "loop" structure, including a non-complementary nucleotide molecule, i.e., a single-stranded region. Even if the two regions of the nucleotide molecule are not completely complementary, the double-stranded portion of the nucleotide can remain in a double-stranded state. For example, insertion, deletion, substitution, etc. may result in a small region being non-complementary or the small region itself forming a stem-loop structure or other forms of secondary structure, however, the two regions may still be substantially complementary and interact in a predictable manner to form a double-stranded region of the stem-loop structure. The stem-loop structure is well known to those skilled in the art, and generally after obtaining a nucleic acid having a nucleotide sequence with a primary structure, those skilled in the art can determine whether the nucleic acid can form a stem-loop structure.

[0052] As used herein, "the function is the same or substantially the same as miR-302" means retaining ≥50%, ≥60%, ≥70%, ≥80%, ≥90% of the function of miR-302b in reversing the aging process (for example, restoring the cell cycle or cell proliferation of senescent cells).

[0053] The present application also includes miRNA variants and derivatives. A person skilled in the art can modify miR-302 using a common method, including (but not limited to): methylation modification, locked nucleotide modification, nucleic acid modification, hydrocarbon modification, glycosylation modification, peptide modification, lipid modification, halogen modification, etc.

[0054] In one specific example, an agonist of a miRNA includes a substance that promotes miRNA expression or promotes the functional activity of a miRNA, for example, a miRNA mimic comprising a polynucleotide of the initial miRNA (pri-miRNA), precursor miRNA (pre-miRNA) or mature sequence of miR-302a, miR-302b, miR-302c, miR-302d, miR-302e, miR-302f and / or miR-367.

[0055] In a specific example, the miRNA is derived from humans or other animals; preferably, the other animals are one or more of monkeys, cats, dogs, rats and mice.

[0056] In a specific example, the miR-302 / miR367 family comprising the 5'-AAGUGCU-3' core sequence is selected from one or more of the following groups: hsa-miR-302a-3p, hsa-miR-302b-3p, hsa-miR-302c-3p.1, hsa-miR-302d-3p, hsa-miR-302e, bta-miR-302b, bta-miR-302c, bta-miR-302d, gga-miR-302b-3p, gga-miR-302c-3p, gga-miR-302d, mdo-miR-302a-3p, mdo-miR-302e-3p.2, b, mdo-miR-302c, mdo-miR-302d, mml-miR-302a-3p, mml-miR-302b, mml-miR-302c, mml-miR-302d, mmu-miR-302a-3p, mmu-miR-302b-3p, mmu-miR-302d-3p, ptr-miR-302a, ptr-miR-302b, ptr-miR-302c, ptr-miR-302d, ptr-miR-302e; and / or, the miR-302 / miR367 family comprising the 5'-CUUAAAC-3' core sequence is selected from one of the following groups or more: hsa-miR-302a-5p, cfa-miR-302a and mmu-miR-302a-5p; and / or, the miR-302 / miR367 family comprising the 5'-CUUUAAC-3' core sequence is selected from one or more of the following groups: hsa-miR-302b-5p, hsa-miR-302d-5p, cfa-miR-302b, cfa-miR-302d, gga-miR-302b-5p, mmu-miR-302b-5p, mmu-miR-302c-5p and mmu-miR-302d-5p; and / or, the miR-302 / miR367 family comprising the 5'-CUUUAAC-3' core sequence is selected from one or more of the following groups: hsa-miR-302b-5p, hsa-miR-302d-5p, cfa-miR-302b, cfa-miR-302d, gga-miR-302b-5p, mmu-miR-302b-5p, mmu-miR-302c-5p and mmu-miR-302d-5p; and / or, the miR-302 / miR367 family comprising the 5'-AGUGCUU-3' core sequence The miR-302 / miR367 family of the core sequence is selected from one or more of the following groups: bta-miR-302a, gga-miR-302a, mmu-miR-302c-3p; and / or, the miR-302 / miR367 family comprising the 5'-UUAACAU-3' core sequence is selected from one or more of the following groups: hsa-miR-302c-5p, cfa-miR-302c and gga-miR-302c-5p; and / or, the miR-302 / miR367 family comprising the 5'-AAUUGCU-3' core sequence is selected from hsa-miR-302f and / or ptr-miR-302f;And / or, the miR-302 / miR367 family comprising the 5'-CUGUUGC-3' core sequence is selected from hsa-miR-367-5p, cfa-miR-367, mmu-miR-367-5p; and / or, the miR-302 / miR367 family comprising the 5'-AUUGCAC-3' core sequence is selected from hsa-miR-367-3p, mml-miR-367, mmu-miR-367-3p, ptr-miR-367, xtr-miR-367. ;

[0057] In a specific example, the miRNA is a miRNA in the miR-302 / 367 family, and the miR-302 / 367 family includes: miR-302 and / or miR-367, or a modified derivative of miR-302 or miR-367, whose function is the same or substantially the same as that of miR-302b or miR-367. Among them, the miRNA can be a mature miRNA, and the above mature miRNA sequence and its gene coding sequence may have base differences between different species, but it does not affect the performance of its function.

[0058] In a specific example, miR-302 includes one or more of miR-302a, miR-302b, miR-302c, miR-302d, miR-302e and miR-302f; optionally, miR-302a includes miR-302a-3p and / or miR-302a-5p; miR-302b includes miR-302b-3p and / or miR-302b-5p; miR-302c includes miR-302c-3p and / or miR-302c-5p; miR-302d includes miR-302d-3p and / or miR-302d-5p; miR-367 includes miR-367-3p and / or miR-367-5p;

[0059] In a specific example, the miRNA is selected from the following miRNAs in the miR-302 / 367 family:

[0060] hsa-miR-302a-3p(MIMAT0000684)、hsa-miR-302b-3p(MIMAT0000715)、hsa-miR-302c-3p.1(MIMAT0000717)、hsa-miR-302d-3p(MIMAT0000718)、hs a-miR-302e(MIMAT0005931)、bta-miR-302b(MIMAT0009280)、bta-miR-302c(MIMAT0009281)、bta-miR-302d(MIMAT0009279)、gga-miR-302b-3p(MI MAT0003357), gga-miR-302c-3p (MIMAT0003359), gga-miR-302d (MIMAT0003360), mdo-miR-302a (MIMAT0004182), mdo-miR-302b (MIMAT0004180), mdo-miR-302c (MIMAT0004181), mdo-miR-302d (MIMAT0004183), mml-miR-302a-3p (MIMAT0006259), mml-miR-302b (MIMAT0006260), mml-miR-302c (M (MIMAT0006261), mml-miR-302d(MIMAT0006262), mmu-miR-302a-3p(MIMAT0000380), mmu-miR-302b-3p(MIMAT0003374), mmu-miR-302d-3p(MIMAT0003377), ptr-miR-302a(MIMAT0008086), ptr-miR-302b(MIMAT0008087), ptr-miR-302c(MIMAT0008088), ptr-miR-302d(MIMAT0008089), ptr-miR-30 2e(MIMAT0008090)、hsa-miR-302a-5p(MIMAT0000683)、cfa-miR-302a(MIMAT0009855)、mmu-miR-302a-5p(MIMAT0004579)、hsa-miR-302b-5p(MIMA T0000714)、hsa-miR-302d-5p(MIMAT0004685)、cfa-miR-302b(MIMAT0009856)、cfa-miR-302d(MIMAT0009858)、gga-miR-302b-5p(MIMAT0003356)、mmu-miR-302b-5p(MIMAT0003373), mmu-miR-302c-5p(MIMAT0003375), mmu-miR-302d- 5p(MIMAT0017225), bta-miR-302a(MIMAT0009278), gga-miR-302a(MIMAT0001143), mmu -miR-302c-3p(MIMAT0003376), hsa-miR-302c-5p(MIMAT0000716), cfa-miR-302c(MIMA T0009857), gga-miR-302c-5p (MIMAT0003358), hsa-miR-302f (MIMAT0005932), ptr-miR -302f(MIMAT0008091), hsa-miR-367-5p(MIMAT0004686), cfa-miR-367(MIMAT0009859) , mmu-miR-367-5p(MIMAT0017214), hsa-miR-367-3p(MIMAT0000719), mml-miR-367(MIM AT0006292), mmu-miR-367-3p (MIMAT0003181), ptr-miR-367 (MIMAT0008118), gga-miR- 367 (MIMAT0003369), mml-miR-302a-5p (MIMAT0026851) and xtr-miR-367 (MIMAT0003638). ,

[0061] The number in brackets is the accession number, which can be queried in the mirbase database.

[0062] In a preferred example, the miRNA is selected from the following miRNAs in the miR-302 / 367 family: one or more of hsa-miR-302a-3p, hsa-miR-302a-5p, hsa-miR-302b-3p, hsa-miR-302b-5p, hsa-miR-302c-3p, hsa-miR-302c-5p, hsa-miR-302d-3p, hsa-miR-302d-5p, hsa-miR-302e, hsa-miR-302f, hsa-miR-367-5p and hsa-miR-367-3p, or selected from nucleotides with a homology of ≥75% with the above miRNA sequences, preferably a homology of ≥85%, more preferably a homology of ≥95%, and optimally a homology of ≥99%. Furthermore, the miRNA includes the nucleotide sequences shown in SEQ ID NOs: 1-14.

[0063] According to the miRNA sequence provided in the present application, a person of ordinary skill in the art can design a polynucleotide (construct) that can be processed into a miRNA that can affect the expression of the corresponding mRNA after being introduced, that is, the polynucleotide (construct) can upregulate the function of the corresponding miRNA in vivo. Therefore, one embodiment of the present application also provides a separated polynucleotide (construct), the polynucleotide (construct) can be transcribed into a precursor miRNA by a human cell, and the precursor miRNA can be cleaved and expressed into the miRNA by a human cell.

[0064] Usually, the polynucleotide construct is located on an expression vector. Therefore, the present application also includes a vector containing the miRNA, or the polynucleotide (construct). The expression vector usually also contains a promoter, a replication origin and / or a marker gene, etc. Methods well known to those skilled in the art can be used to construct the expression vector required for the present invention. These methods include in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology, etc. The expression vector preferably contains one or more selective marker genes to provide phenotypic traits for selecting transformed host cells.

[0065] In a specific example, the derivative or the expression vector described in or described in the polynucleotide comprises the structure shown in Formula I:

[0066] Seq 正向 -X-Seq 反向 Formula I;

[0067] In Formula I, Seq 正向 is a nucleotide sequence that can be processed into any miRNA in the miRNA-302 / miRNA-367 family in the host, Seq 反向For Seq 正向 Substantially complementary nucleotide sequences; or, Seq 反向 is a nucleotide sequence that can be processed into any miRNA in the miRNA-302 / miRNA-367 family in the host, Seq 正向 For Seq 反向 Substantially complementary or completely complementary nucleotide sequences; X is a spacer sequence located between Seq forward and Seq reverse, and the spacer sequence is 正向 and Seq 反向 Not complementary;

[0068] And after the structure shown in Formula I is transferred into the host, a secondary structure shown in Formula II is formed:

[0069]

[0070] In Formula II, Seq 正向 , Seq 反向 and X is defined as above,

[0071] || means in Seq 正向 and Seq 反向 The base pairing relationship formed between them.

[0072] In a preferred example, the precursor miRNA or the polynucleotide or the expression vector comprises a nucleotide sequence as shown in any one of SEQ ID Nos: 1 to 14, for example, the nucleotide sequence of the precursor miR-302b is shown in SEQ ID No: 15.

[0073] In a specific example, the expression vector can be selected from a viral vector or a non-viral vector, wherein the non-viral vector includes one or more of a plasmid, a phage, a lipid nanoparticle (LNP), a transfection reagent and an exosome.

[0074] Optionally, the plasmid includes a combination of one or more of pCMV-myc, pcDNA3.0, pcDNA3.1 and Minicircle.

[0075] Preferably, the plasmid is Minicircle, which can carry the target gene with a minimum number of bp and can be continuously expressed in animals.

[0076] Optionally, the viral vector is selected from one or more of a retroviral vector, a lentivirus, an adenoviral vector, an adeno-associated viral vector, a herpes virus vector, an alphavirus vector, a baculovirus and a vaccinia virus, preferably an adeno-associated viral vector, such as an AAV virus.

[0077] One embodiment of the present application also provides the use of the above-mentioned active ingredients in the preparation of products for reversing the aging process of senescent cells.

[0078] One embodiment of the present application also provides the use of the above-mentioned active ingredients in the preparation of products for restoring the cell cycle or cell proliferation ability of senescent cells.

[0079] One embodiment of the present application also provides the use of the above-mentioned active ingredients in the preparation of products for treating related diseases caused by cell aging.

[0080] In a specific example, the related diseases caused by cell aging include one or more of skin aging, hair loss, gray hair, hypertension, cardiovascular and cerebrovascular diseases, degenerative joint diseases, osteoporosis, diabetes, abnormal lipid metabolism, fatty liver, cirrhosis, gonadal atrophy, overactive bladder, renal dysfunction, depression, Parkinson's disease, Alzheimer's disease, multiple organ function degeneration, cataracts, tooth loss and hearing impairment.

[0081] In a specific example, abnormal lipid metabolism has one or more characteristics of excessive fatty acid synthesis, abnormal signaling pathways for de novo fatty acid synthesis (such as mTORC2 signaling), and abnormal expression of downstream rate-limiting enzymes related to de novo fatty acid synthesis.

[0082] In one specific example, overactive bladder is characterized by one or more of urinary frequency, urinary urgency, with and without urge incontinence.

[0083] In one specific example, treating overactive bladder comprises alleviating symptoms of frequent urination, urgency and / or urge incontinence in an aged animal. Optionally, the animal comprises a human, a cat, a dog, a rat or a mouse.

[0084] In one specific example, the product includes a formulation and / or a pharmaceutical composition.

[0085] In a specific example, the drug includes any of the active ingredients described above and a pharmaceutically acceptable excipient or carrier.

[0086] In a specific example, the excipients include solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesive agents, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids and release retardants. One or more.

[0087] In a specific example, the pharmaceutically acceptable carrier is selected from the group consisting of water, saline, liposomes, lipids, proteins, protein-antibody conjugates, peptides, cellulose, nanogels, or combinations thereof. The choice of carrier should match the mode of administration, which are well known to those of ordinary skill in the art.

[0088] Generally, the dosage form of the drug should match the mode of administration. In a specific example, the dosage form of the drug of the present application includes one or more of injection, oral liquid, suspension, emulsion, extract, powder, granule, suppository, aerosol, transfection agent, tablet and capsule.

[0089] The drugs described in the present application can be administered alone or in combination with other drugs capable of treating the same disease.

[0090] One embodiment of the present application also provides a pharmaceutical composition, which comprises any of the active ingredients described above.

[0091] One embodiment of the present application also provides a method for reversing aging, using the above active ingredient or pharmaceutical composition to reverse the aging of a subject. The reversal of aging includes reversing the aging of an individual or reversing the aging of senescent cells.

[0092] In a specific example, the DNA sequence encoding the above-mentioned miRNA is used as the target gene, such as miR-302b (SEQ ID No: 15), an overexpression vector of the miRNA is constructed, and a drug containing the miRNA overexpression vector is prepared and administered via an ex vivo or in vivo administration route.

[0093] Specifically, a person skilled in the art can administer the drug via an ex vivo administration route: the drug of the miRNA overexpression vector is introduced or transfected into the individual's own or allogeneic cells in vitro, and then the cells are amplified in vitro and then injected back into the individual.

[0094] Specifically, a person skilled in the art may also administer the drug via an in vivo administration route: directly introducing the drug of the miRNA overexpression vector into an individual.

[0095] The effective amount of the active ingredient described in the present application may vary depending on the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). Among them, factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated, the patient's weight, the patient's immune status, the route of administration, etc.

[0096] One embodiment of the present application also provides an in vitro non-therapeutic method for reversing aging, or a method for restoring the cell cycle or cell proliferation ability of senescent cells, the method comprising: adding the pharmaceutical composition of the present application or the active ingredient of the present application to the cultured senescent cells, thereby reversing the aging process of the senescent cells, and allowing the senescent cells to return to the cell cycle and proliferate.

[0097] The embodiments of the present application will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are preferably referred to the guidance provided in the present application, and can also be based on the experimental manual or normal conditions in this area, can also be based on the conditions recommended by the manufacturer, or refer to experimental methods known in the art.

[0098] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.

[0099] Example 1 Doxorubicin induces senescence of p21-YFP-Neo cell line

[0100] In the early stage of the research, the inventor used CRISPR / Cas9 technology to perform gene editing with the help of Cas9, gRNA, and p21-YFP donor. Specifically, the YFP gene fragment was inserted into the position of the terminator codon of p21 in the LO2 cell line, and the LO2-P21-YFP positive cell line was screened.

[0101] Specifically, constructing a CRISPR / Cas9 vector: constructing a CRISPR / Cas9 vector using a gRNA sequence, wherein the sequence of the gRNA is GGCTTCCTGTGGGCGGATTA, SEQ ID No: 25.

[0102] Synthesis of p21-YFP donor plasmid: First, insert the sequence of the YFP coding gene (bases at positions 3536 to 4252 shown in SEQ.ID No: 26) into the Venus-P2A-Neo plasmid to prepare the YFP-P2A-Neo plasmid. Using LO2 cell genomic DNA and the YFP-P2A-Neo plasmid as templates, use the primers in Table 1 to amplify the Vector fragment, p21Upstream fragment, YFP-NeoR fragment, and p21Downstream fragment, and use the Gibson reaction system to assemble the above four fragments into the p21-YFP donor plasmid (the donor plasmid sequence is shown in SEQ.ID No: 26). The above experiments were all performed by Sangon Biotech.

[0103] Table 1

[0104]

[0105] Furthermore, the CRISPR / Cas9 vector containing gRNA and the p21-YFP donor plasmid were co-transfected into LO2 cells to screen the LO2-P21-YFP positive cell line.

[0106] Furthermore, Doxorubicin was used to induce senescence of the LO2-P21-YFP cell line, and a senescent cell model was obtained after flow cytometry sorting using YFP.

[0107] P21 (cyclin-dependent kinase inhibitor p21, CDKN1A) is an important aging marker. P21 is the downstream CDKI of phosphorylated P53, which blocks the cell cycle from entering the G1 / S cell cycle by binding to CDK2. High expression of P21 is associated with aging.

[0108] Doxorubicin is a DNA topoisomerase inhibitor, commonly used in tumor treatment, and can induce cell senescence at a low concentration of 50nM. Due to the quinone-hydroquinone structure on the anthracene ring ligand in the Doxorubicin molecule, it has the ability to accept electrons and provide neutrons, inserting between adjacent base pairs of DNA to generate active free radicals, causing the DNA double helix to unwind, DNA chain to break, inhibiting the template activity of nucleic acids, interfering with the transcription process, and inhibiting mRNA synthesis. In addition, it may also cause cell membrane rupture and exhibit cytotoxic effects. It is a non-specific drug for the cell cycle and has an effect on cells in all phases, but is most sensitive to the early S phase, followed by the M phase, and least sensitive to the G1 phase, and has a delaying effect on the G1, S and G2 phases.

[0109] Specifically, the steps of inducing senescence of the p21-YFP-Neo cell line by Doxorubicin include the following:

[0110] (1) 0.3x10 6 p21-YFP-Neo cells were seeded into 35 mm laser confocal cell culture dishes and cultured for 12 hours.

[0111] (2) After the cells adhered, the medium was changed and culture medium containing 50 nM / L Doxorubicin was added.

[0112] (3) After 24 hours, replace the culture medium with normal culture medium.

[0113] (4) After 4 days of culture, YFP was used for flow cytometry sorting to observe the expression of p21-YFP in the sorted cells.

[0114] (5) Perform senescence-related β-galactosidase staining.

[0115] Wherein, the β-galactosidase staining method comprises the following steps:

[0116] Dilute 10X Fixative Solution to 1X, and thoroughly dissolve and dilute the Staining Solution to 1X in a 37°C water bath; dissolve 20 mg of X-gal in DMF and store at -20°C away from light; prepare the staining solution, add 1 mL of staining solution to each well of a 6-well plate, 930 μL 1X Staining Solution, 10 μL 100X Staining Solution A, 10 μL 100X Staining Solution B and 50 μL 20 mg / mL X-gal to make 1 mL of staining solution, and adjust the pH to pH = 6.0; remove the cell culture supernatant, add PBS to wash twice, add 1 mL 1X Fixative Solution to each empty space of the 6-well plate and fix at room temperature for 15 minutes; remove the fixative, wash once with PBS, add the staining solution, and place in a carbon dioxide-free incubator at 37°C for staining for 12 hours; place the culture dish under a microscope to observe the staining.

[0117] By setting the gate with FITC fluorescence, YFP-positive cells were selected for sorting. The results are as follows: Figure 1A shown.

[0118] The sorted cells were plated and 0.3×10 6 The cells were seeded in 35 mm cell culture dishes and imaged by fluorescence microscopy. Figure 1B As shown, Doxorubicin can induce the expression of p21-YFP.

[0119] β-galactosidase staining results Figure 1C As shown, the addition of Doxorubicin can induce senescence of the LO2-p21-YFP cell line, indicating that the cell senescence model was successfully constructed.

[0120] Example 2: miR-302b causes senescent cells to regain their proliferation capacity

[0121] We previously discovered that the miR302 / 367 family is highly expressed in ES and iPS exosomes (Youkun Bi et al. Systemic proteomics and miRNA profile analysis of exosomes derived from human pluripotent stem cells. Stem Cell Res Ther. 2022 Sep 5; 13(1): 449.). After a large number of studies, it was found that stem cell exosomes can induce senescent LO2 cells to return to the cell cycle. To further study whether small RNAs in exosomes have this phenomenon, the following experiments were conducted:

[0122] The miR-302b mimic was synthesized by Sangon Biotechnology, prepared into a 20 μM solution, and stored at -20°C for 6 months.

[0123] The sequence is as follows:

[0124] The sequences of miR-302b-3p and miR-302b-5p are:

[0125] 5'-UAAGUGCUUCCAUGUUUUAGUAG-3', SEQ ID No: 3 and 5'-ACUUUAACAUGGAAGUGCUUUC-3', SEQ ID No: 4;

[0126] Using the method in Example 1, 50 nM Dox was used to induce LO2 cell senescence. Figure 2 It can be seen that after 24 hours of induction, the cells in the Dox group became significantly larger, and the number decreased compared with the control group, and the senescent cells were sorted. After adding 7.5μL miR-302b mimic (Dox-miR-302b group, final concentration 50nM) to the Dox-induced senescent cells and culturing for 2 days, it was found that the cells increased significantly compared with the Dox-Vehicle group (control group).

[0127] To verify whether the addition of miR-302b to senescent cells resulted in proliferation, we induced cell senescence in a 35 mm confocol dish according to the method in Example 1, sorted out senescent cells, and grouped them into a Dox+PBS group (7.5 μL PBS was added to 3 mL culture medium) and a Dox+320B group (7.5 μL 20 mM miR-302b mimic was added to 3 mL culture medium, so that the final concentration of miR-302b mimic in the culture medium was 50 nM). We further used a high-content laser confocal cell imaging analysis system (Opera Phenix, PerkinElmer Enterprise Management Co., Ltd.) live cell workstation, such as Figure 3As shown in Figure 2, we tracked the proliferation of single cells to which 50 nM miR-302b mimic was added. The definition of cell senescence is a permanent cell cycle arrest state, which also means that the definition of senescent cells will be rewritten, that is, senescent cells are not permanently arrested in the cell cycle, but temporarily stopped, and the cell cycle can be restored by exogenous factors.

[0128] The miR302 / miR367 family is evolutionarily conservative and is expressed in many species such as primates, other mammals, amphibians, birds, etc. In the human genus, the miR302 / miR367 family is divided into miR-302a, miR-302b, miR-302c, miR-302d, miR-302e, miR-302f, and miR-367. Senescent cells were cultured and sorted according to the method in Example 1, and human miR-302a, miR-302b, miR-302c, miR-302d, miR-302e, miR-302f, and miR-367 were transfected into senescent cells at 50nM using Lipo3000 (Thermo Company). The changes in cell viability over time were statistically analyzed, as shown in Figure 1. Figure 4 As shown, the cell viability of the control group (normal LO2 cells, Con) was close to 100%, the initial viability of the Dox-treated group was about 50%, and then gradually decreased over time to about 30% at 48 hours, and the miRNA transfection group showed a gradual increase in viability (miR-302a, miR-302b, miR-302c, miR-302d, miR-302e), or the viability did not change much but did not decrease (miR-302f, miR-367), which suggests that the miR302 / miR367 family has a certain ability to reverse aging.

[0129] The sequence is as follows, and the corresponding double-stranded miRNA mimic is synthesized by Bio-engineering:

[0130] hsa-miR-302a-5p MIMAT0000683:

[0131] 5'-ACUUAAACGUGGAUGUACUUGCU-3', SEQ ID No: 1;

[0132] hsa-miR-302a-3p MIMAT0000684:

[0133] 5'-UAAGUGCUUCCAUGUUUUGGUGA-3'; SEQ ID No: 2;

[0134] miR-302b-3p_MIMAT0000715:

[0135] 5'-UAAGUGCUUCCAUGUUUUAGUAG-3', SEQ ID No: 3;

[0136] miR-302b-5p_MIMAT0000714:

[0137] 5'-ACUUUAACAUGGAAGUGCUUUC-3', SEQ ID No: 4;

[0138] hsa-miR-302c-5p MIMAT0000716:

[0139] 5'-UUUAACAUGGGGGGUACCUGCUG-3', SEQ ID No: 5;

[0140] hsa-miR-302c-3p MIMAT0000717:

[0141] 5'-UAAGUGCUUCCAUGUUUCAGUGG-3', SEQ ID No: 6;

[0142] hsa-miR-302d-5p MIMAT0004685:

[0143] 5'-ACUUUAACAUGGAGGCACUUGC-3', SEQ ID No: 7;

[0144] hsa-miR-302d-3p MIMAT0000718:

[0145] 5'-UAAGUGCUUCCAUGUUUGAGUGU-3', SEQ ID No: 8;

[0146] hsa-miR-302e MIMAT0005931:

[0147] Forward sequence: 5'-UAAGUGCUUCCAUGCUU-3', SEQ ID No: 9;

[0148] Reverse sequence: 5'-AUUCACGAAGGUACGAA-3', SEQ ID No: 10;

[0149] hsa-miR-302f MIMAT0005932:

[0150] Forward sequence: 5'-UAAUUGCUUCCAUGUUU-3', SEQ ID No: 11;

[0151] Reverse sequence: 5'-AUUAACGAAGGUACAAA-3', SEQ ID No: 12;

[0152] hsa-miR-367-3p MIMAT0000719:

[0153] 5'-AAUUGCACUUUAGCAAUGGUGA-3', SEQ ID No: 13;

[0154] hsa-miR-367-5p MIMAT0004686:

[0155] 5'-ACUGUUGCUAAUAUGCAACUCU-3', SEQ ID No: 14.

[0156] Example 4 miR-302b causes senescent cells to re-enter the cell cycle

[0157] Cell senescence was induced according to the method of Example 1, and Dox-induced senescent cells were screened by flow cytometry.

[0158] Senescent cells were plated and 0.3×10 6 In the Dox-miR-302b group, 50 nM miR-302b mimic was added to each well and treated for 3 days; in the Dox-PBS group, 5 μl PBS solution was added to each well and treated for 3 days. The LO2 normal cell group (Con) was set as a control, and the cells were collected for cell cycle detection.

[0159] Specifically, the cells were digested with a pancreatic enzyme substitute and centrifuged at 1000×g for 5 minutes. The cells were washed with 1 mL of pre-cooled saline, centrifuged at 1000xg for 5 minutes, and the supernatant was carefully aspirated. When aspirating, 50μl of supernatant remained to avoid aspirating the cells. The bottom of the centrifuge tube was flicked to properly disperse the cells to avoid cell clumping. 1 mL of pre-cooled 70% ethanol was added, and the mixture was gently blown to mix. The cells were fixed at 4°C for 24 hours. Centrifuged at 1000×g for 5 minutes, the supernatant was discarded, and 50μl of supernatant remained to avoid aspirating the cells. 1 mL of pre-cooled saline was added to wash the cells once. 0.5 mL of PI staining solution was added to each tube of sample, the cells were slowly and fully resuspended, and the cells were stained at 37°C in the dark for 30 minutes. After staining, the cells were detected by flow cytometry with an excitation wavelength of 488nm.

[0160] The preparation of PI staining solution: 500 μl of staining buffer, 25 μl of PI staining solution (20×), 10 μl of RNaseA, and a total volume of 535 μl.

[0161] The results are as follows Figure 5The results showed that about 22% of LO2 normal cells (LO2-PBS group) were in the S phase, about 2% of LO2 cells were in the S phase after Dox-induced senescence (LO2-Dox-PBS group), and about 8% of LO2 cells were in the S phase after adding miR-302b after Dox-induced senescent cells (LO2-Dox-miR-302 group), which was significantly higher than the LO2-Dox-PBS group. This is consistent with the above results, that is, miR-302b can reverse senescence.

[0162] Furthermore, Ki67 staining was performed. Ki67 is a nuclear protein and a cell proliferation marker. Figure 6 The results show that most cells in the LO2-Dox-miR-302 group were in a proliferative state, while almost no cells in the LO2-Dox-PBS group were in a proliferative state.

[0163] Example 5 Preparation of adeno-associated virus expressing mir-302b throughout the body

[0164] (1) The sequences of miR-302b-3p and miR-302b-5p are: 5'-UAAGUGCUUCCAUGUUUUAGUAG-3', SEQ ID No: 3 and 5'-ACUUUAACAUGGAAGUGCUUUC-3', SEQ ID No: 4; the designed precursor sequence (WT) is as follows: 5'-GCTCCCTTCAACTTTAACATGGAAGTGCTTTCTGTGACTTTAAAAGTAAGTGCTTCCATGTTTTAGTAGGAGT-3', SEQ ID No: 15. The upstream flanking sequence (200 bp), the downstream flanking sequence (200 bp) and the final synthetic sequence are as follows:

[0165] 5'-

[0166] aaaggaattcaagagttaagaatagtataaatagaagtggctgaagtccctgccttttacccttctggaggagaacacgaatctttgggaactagttcaggaaggtaaaa

[0167] aaatttttttcttctaaagttatgccattttgttttctttctcctcagctctaaatactctgaagtccaaagaagttgtatgttgggtggGCTCCCTTCAACTTTAA

[0168] CATGGAAGTGCTTTCTGTGACTTTAAAAGTAAGTGCTTCCATGTTTTAGTAGGAGTgaatccaatttacttctc

[0169] caaaatagaacacgctaacctcatttgaagggatcccctttgctttaacatgggggtacctgctgtgtgaaacaaaagtaagtgcttccatgtt tcagtggaggtgtctccaagccagcacaccttttgttacaaaatttttttgttattgtgttttaaggttaactaagcttgttacaggtt-3', SEQ ID No:16.

[0170] (2) The AAV vector rAAV-CMV-sfGFP-3×FLAG-WPRE provided by Heyuan Biotechnology Co., Ltd. was used to construct a recombinant vector overexpressing miR-302b. The above-mentioned final synthetic sequence was inserted into the downstream of the CMV promoter in the expression vector by homologous recombination to construct a recombinant plasmid (for specific construction methods, refer to Figure 7 ), picked clones and sent them to the company for sequencing, and the correctly sequenced plasmid was named AAV-miR-302b.

[0171] (3) The recombinant vector constructed in step (2) was transfected into HEK293T cells, and cell samples were collected after 24 hours to extract miRNA. The miR-302b content in the cells was determined by real-time quantitative PCR using the tailing method.

[0172] (4)7×10 6 HEK293T cells / well were inoculated into 15 cm culture dishes. The cell culture medium was DMEM containing 10% FBS. The dishes were placed in a 37°C, 5% CO2 incubator for about 24 hours to allow the cell confluence to reach 70% to 80%. Before cell transfection, the complete culture medium was replaced with Opti-DMEM culture medium. The transfection reagent Tubofect TM Transfection Reagent (Invitrogen, Cat #R0532) was transfected, and the specific steps were as follows: take a 5mL DNase / RNase-free centrifuge tube, add 500μL Opti-DMEM medium, add the recombinant expression plasmid rAAV-TBG-miR-302b (20μg), serum type plasmid rAAV2 / 8-Rep / Cap (10μg) and virus packaging auxiliary plasmid rAAV-Helper (30μg) to the above centrifuge tube, and vortex mix; take another 5mL DNase / RNase-free centrifuge tube, add 500μL Opti-DMEM medium, add 120μL Tubofect according to the ratio of plasmid mass: transfection reagent volume = 1:2, and vortex mix; mix the two tubes of solution and let it stand at room temperature for 15min; slowly add the liquid after standing to the HEK293T cells prepared previously, drop it in a concentric circle manner, shake it slightly while adding, and then place it at 37℃, 5% CO2 incubator. After 12 h, Opti-DMEM was replaced with complete medium. The recombinant AAV packaging process is shown in Figure 8 .

[0173] (5) Observe the cell status. During this period, an appropriate amount of complete culture medium can be added to the culture dish. The packaged virus was collected 72 hours after transfection. The specific steps are as follows: collect the cell supernatant and the cells into the same centrifuge tube, centrifuge at 2100×g for 10 min at room temperature, then transfer the supernatant to a new centrifuge tube, precipitate with PEG 8000 overnight (add 2.33g NaCl and 8.5g PEG 8000 for every 100mL supernatant), and the next day, centrifuge at 3500×g and 4°C for 30min, immediately discard the supernatant to prevent the virus from re-dissolving, and resuspend in 2mL PBS+0.001% PF68; resuspend the above centrifuged cell pellet with 2mL PBS+0.001% PF68, freeze-thaw repeatedly at -80°C and 37°C for 3 times, and add 2mL 5M NaCl (autoclaved); mix the above PEG-precipitated cell supernatant and the resuspended cell pellet, oscillate and sonicate (sonicate for 30s, stop for 8-10s), and AMPL Ultrasonicate at 30% for 3 to 4 times. If the viscosity of the sample decreases, switch to AMPL 20% for 1 time (the purpose of switching the ultrasound intensity is to prevent excessive ultrasound intensity from affecting the activity of the virus); centrifuge the liquid after ultrasound at 3500×g and 4°C for 30 minutes, and transfer the supernatant to a new centrifuge tube.

[0174] (6) Purify the prepared AAV using iodixanol gradient centrifugation. The specific method is as follows: prepare different concentrations of iodixanol (iodixanol and sterile water are prepared according to the mass / volume ratio (Table 2) and then filtered through a 0.22 μm filter membrane); take a high-pressure sterilized ultracentrifuge tube and add different concentrations of iodixanol layer by layer, from bottom to top, 4.2 mL 60% layer, 5 mL 40% layer, 6 mL 25% layer, 9 mL 15% layer (when adding different concentrations of iodixanol, the centrifuge tube should be tilted to avoid layer confluence. The density difference between the 15% layer and the 25% layer is small, so special attention should be paid). The whole process is carried out in a biological safety cabinet; slowly add the virus prepared in step (5) to the upper layer, balance the centrifuge tube (control the error within 0.01 g), prepare a VTi50 rotor, and centrifuge at 48,000 rpm and 4°C for 150 min.

[0175] Table 2. Iodixanol density gradient centrifugation solution preparation.

[0176]

[0177] (7) After ultracentrifugation, puncture the bottom of the ultracentrifugation tube with a needle, discard the 2 mL of liquid that drips, collect the 3rd to 7th mL of liquid, add double antibody to the collected virus, treat at 37°C for 1 hour, then dilute to an appropriate volume with PBS + 0.001% PF68, and sterilize through a 0.22μm filter membrane; transfer the filtrate to a 100KD ultrafiltration tube, centrifuge at 3500rpm and 4°C for 30min; mix the remaining liquid in the ultrafiltration tube by blowing, aspirate and transfer to a virus collection tube, wash the concentration tube twice with 150μL of PBS + 0.001% PF68, transfer the remaining liquid to a virus collection tube, mark the name and date, and store it at -80°C for a long time.

[0178] (8) Take 10 μL of virus for titer determination. Real-time quantitative PCR is a commonly used method for determining the number of purified virus particles. There is a linear relationship between the Ct value of the template and the logarithm of the initial copy number of the template. A standard curve is drawn using a standard substance with a known copy number, and then the number of virus particles is calculated. The specific operation steps are as follows: dilute the virus sample 10 times, prepare Mixture (DNase / RNase-free ddH2O 4μL, DNAasel 1μL, 10×DNAasel Buffer 1μL, virus diluent 4μL), incubate at 37°C for 30min, and inactivate the DNA enzyme at 95°C for 5min; add 1μL proteinase K (5μg / μL), incubate at 37°C for 30min, then add 30μL ultrapure water, heat at 95°C for 5min to inactivate proteinase K, centrifuge at 12000rpm for 2min, and take the supernatant for qPCR detection; take 5μL of the centrifuged supernatant, dilute 10 times, and take 2μL of the dilution as a template for qPCR; calculation of the number of virus particles: number of virus particles (VP / mL) = relative value to the standard × 1000.

[0179] Example 6: mir-302b reverses aging in mice

[0180] Twenty 24-month-old C57BL / 6 mice were evenly divided into two groups and AAV-miR-302b was administered via tail vein at 50 μl / time once a week for 2 weeks. Fig. 9 As shown, at 30 months of age, the hunchback and hair loss phenomena of the elderly mice in the miR-302b group were significantly alleviated compared with those in the elderly mice group, further suggesting that miR-302b has the ability to reverse aging in animals.

[0181] The results of β-gal staining of mouse multi-organ pathological sections are as follows Fig.10 As shown, the aged mice group showed positive β-gal staining in the lung, liver and spleen, which was significantly alleviated after miR-302b treatment.

[0182] The results of H&E staining of hair follicles are as follows Fig.11 As shown, the results showed that hair follicle atrophy in aged mice was alleviated after miR-302b treatment.

[0183] Animal behavior experiment: Rotarod test was conducted at 29-30 months of age. Fig.12 As shown, the mice were placed on the rotating rod, which was kept at a speed of 25 rpm. The time the mice spent on the rotating rod was counted. After 4 days of learning, the experiment was conducted on the fifth day. The results were as follows Fig.12 As shown in the left figure, the miR-302b treatment group lasted about 65 seconds, which was significantly longer than the control group of about 28 seconds. Further, the grip strength test was conducted. The average of the three grip strength results was divided by the body weight, and the test was conducted every two days. The results are as follows Fig.12 The right figure shows that the miR-302b treatment group is better than the control group. The above results show that the aging of the miR-302b treatment group is significantly alleviated.

[0184] Urine spot test:

[0185] With the onset of aging, mice and humans are often accompanied by overactive bladders, which manifest as frequent urination, urgency, with or without urgency urinary incontinence. Mice show the appearance of small urine spots (diameter ≤ 5mm). Each mouse in each group was operated as follows: the bedding was removed from the bottom of the cage and wiped dry, and a 12cm×25cm filter paper was placed and glued to the bottom of the cage. After the mice were placed in the cage for two hours of adaptation, the filter paper was peeled off and the same filter paper was laid again for recording. During this process, the mice were allowed to eat freely but were not given water. After three hours, the filter paper was removed and photographed using a gel imaging system. The photography parameters were: ultraviolet reflected light, aperture 85, focal length 50, focus 100, gain 35.03dB, contrast 0, gamma 1.1, and exposure time 1.1s.

[0186] The urine spot image of one of the mice in the Aging-PBS group and the Aging+miR-302b group is shown in Fig.13 According to statistics, the number of urine spots in the Aging-PBS group was 46.25±13.75 (N=4), and the number of urine spots in the Aging+miR-302b group was 10.25±2.66 (N=4). Fig.13 As shown in the right figure, the results showed that miR-302b treatment significantly alleviated the symptoms of overactive bladder in aged animals.

[0187] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0188] The above-mentioned embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the patent of the present application shall be subject to the attached claims, and the description and drawings may be used to interpret the contents of the claims.

Claims

1. Use of an active ingredient in the preparation of a product for treating overactive bladder, wherein the active ingredient comprises at least one of the following (1) to (5): (1) miR-302b, modified miR-302b derivatives or miR-302b mimics; (2) a precursor miRNA, which can be processed into the miRNA described in (1) in the host; (3) a polynucleotide, which can be transcribed by a host to form the precursor miRNA described in (2), and processed to form the miRNA described in (1); (4) an expression vector comprising the miRNA described in (1), the precursor miRNA described in (2), or the polynucleotide described in (3); (5) An agonist of the miRNA described in (1).

2. The use according to claim 1, characterized in that: The treatment includes alleviating the symptoms of urinary frequency, urinary urgency and / or urge incontinence in aged animals.

3. The use according to claim 2, characterized in that: The animal includes a human, a cat, a dog, a rat or a mouse.

4. The use according to any one of claims 1 to 3, characterized in that The miR-302b includes miR-302b-3p and / or miR-302b-5p; Optionally, the nucleotide sequence of miR-302b includes at least one nucleotide sequence shown in SEQ ID No: 3 to 4.

5. The use according to any one of claims 1 to 3, characterized in that The precursor miRNA described in (2) or the polynucleotide described in (3) or the expression vector described in (4) comprises a nucleotide sequence as shown in at least one of SEQ ID Nos: 3 to 4.

6. The use according to any one of claims 1 to 3, characterized in that The expression vector described in (4) is a viral vector or a non-viral vector.

7. The use according to claim 6, characterized in that: The viral vector includes one or more of a retroviral vector, a lentivirus, an adenoviral vector, an adeno-associated viral vector, a herpes virus vector, an alphavirus vector, a baculovirus and a vaccinia virus.

8. The use according to claim 6, characterized in that: The non-viral vector includes one or more of a plasmid, a bacteriophage, a lipid nanoparticle, a transfection agent and an exosome.

9. The use according to claim 7 or 8, characterized in that: The adeno-associated virus vector includes AAV virus; the plasmid includes Minicircle.

10. The use according to any one of claims 1 to 3, characterized in that The product comprises the active ingredient and excipients.

11. The use according to claim 10, characterized in that: The excipients include one or more of solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids and release retardants.

12. The use according to claim 10, characterized in that: The dosage form of the product includes one or more of injection, oral liquid, suspension, emulsion, extract, powder, granule, suppository, aerosol, transfection agent, tablet and capsule.